Setterwalls has advised Ascelia Pharma in connection with a private placement

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and the company’s ordinary shares are listed on Nasdaq Stockholm (ticker: ACE).

The subscribers in the private placement include a limited number of Swedish qualified investors and existing larger shareholders. The gross proceeds secure the company’s funding for partnership-related transaction costs and extend the company’s cash runway into 2027.